

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the **“Company”**, together with its subsidiaries, the **“Group”**) on a voluntary basis.

The board (the **“Board”**) of directors (the **“Directors”**) of the Company hereby informs its shareholders and potential investors that, facing the challenging global macroeconomic situation and the increasingly fierce industry market landscape in the first half of 2025, the Group firmly proceeded with its business focus and globalization strategy, continuously explored the domestic market, and accelerated expansion of overseas market layout.

The Board expects that the revenue of the Company for the six months ended 30 June 2025 (the **“Period”**) will increase by approximately 70% to 80% year-on-year as compared to the six months ended 30 June 2024, which is mainly attributable to the following reasons:

1. The core product Toumai Laparoscopic Surgical Robot continued to maintain a strong growth momentum during the Period. Particularly, it secured new orders of 18 units and achieved commercial installation of more than 13 units in overseas markets in the first half of the year, becoming the core engine for revenue growth.
2. SkyWalker Orthopedic Surgical Robot fully leveraged the mature sales network of MicroPort Group in both domestic and overseas markets to achieve rapid coverage and penetration in core regions. At the same time, it independently established presence in emerging regions, creating a “dual driver” model to achieve steady growth.
3. R-ONE Vascular Interventional Surgical Robot gained recognition in the market after approval for launch, and the demand steadily increased.

The Board expects that the Group will record an adjusted net loss¹ not more than RMB125 million during the Period (for the period ended 30 June 2024: RMB218 million), and such decrease by more than 40% in the loss is mainly attributable to (i) the continued and rapid

¹ The Company uses adjusted net loss as a non-HKFRS measure, which does not take into account the impact on losses attributable to share-based payment expenses, changes in the fair value of financial instruments and impairment losses on equity-accounted investees.

growth of operating revenue; and (ii) the improved and optimized operational efficiency under all-round cost reduction and efficiency enhancement.

As of the date of this announcement, the Company is still in the process of preparing and finalising its interim results for the six months ended 30 June 2025. The information contained in this announcement is only based on a preliminary assessment of the consolidated management accounts and relevant information available to the Board as of the date of this announcement, and may be subject to adjustments. The interim results announcement of the Company for the six months ended 30 June 2025 will be published on or before 31 August 2025. Shareholders of the Company and potential investors are advised to read the interim results announcement carefully after its publication.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 17 July 2025

As at the date of this announcement, the executive directors are Dr. He Chao, Ms. Fang Cong and Mr. Liu Yu; the non-executive directors are Mr. Sun Hongbin and Mr. Chen Chen; and the independent non-executive directors are Dr. Li Minghua, Mr. Yao Haisong and Mr. Chung Wai Man.